Cargando…

Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease

Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Caifang, Liu, Lijuan, Zhou, Yangyang, Bian, Zhaoxiang, Wang, Shengpeng, Wang, Yitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580650/
https://www.ncbi.nlm.nih.gov/pubmed/31236131
http://dx.doi.org/10.1186/s13020-019-0245-x
_version_ 1783428064108085248
author Gao, Caifang
Liu, Lijuan
Zhou, Yangyang
Bian, Zhaoxiang
Wang, Shengpeng
Wang, Yitao
author_facet Gao, Caifang
Liu, Lijuan
Zhou, Yangyang
Bian, Zhaoxiang
Wang, Shengpeng
Wang, Yitao
author_sort Gao, Caifang
collection PubMed
description Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed.
format Online
Article
Text
id pubmed-6580650
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65806502019-06-24 Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease Gao, Caifang Liu, Lijuan Zhou, Yangyang Bian, Zhaoxiang Wang, Shengpeng Wang, Yitao Chin Med Review Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed. BioMed Central 2019-06-17 /pmc/articles/PMC6580650/ /pubmed/31236131 http://dx.doi.org/10.1186/s13020-019-0245-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Gao, Caifang
Liu, Lijuan
Zhou, Yangyang
Bian, Zhaoxiang
Wang, Shengpeng
Wang, Yitao
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title_full Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title_fullStr Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title_full_unstemmed Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title_short Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
title_sort novel drug delivery systems of chinese medicine for the treatment of inflammatory bowel disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580650/
https://www.ncbi.nlm.nih.gov/pubmed/31236131
http://dx.doi.org/10.1186/s13020-019-0245-x
work_keys_str_mv AT gaocaifang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease
AT liulijuan noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease
AT zhouyangyang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease
AT bianzhaoxiang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease
AT wangshengpeng noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease
AT wangyitao noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease